Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28949912 | 0.94 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL21831286 | 0.88 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL198552 | 0.86 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14488009 | 0.84 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL18309215 | 0.84 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL29013792 | 0.84 | CA1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL10610953 | 0.83 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4640174 | 0.83 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2484883 | 0.82 | TSHR (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL31455691 | 0.82 | CA1 (0.52) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109896998-B | 3, 4-dihydroisoquinoline sulfonamide compound and application thereof | 复旦大学 | 2022-06-07 | — | — | CN | disclosed |
| EP-2940017-B1 | Process for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMA (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-07-04 | — | — | US | disclosed |
| US-9862709-B2 | Processes for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-09 | — | — | US | disclosed |
| US-9737522-B2 | NMDA receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-01 | — | — | US | disclosed |
| US-20150196540-A1 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-07-16 | — | — | US | disclosed |
| US-9035053-B2 | Processes for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-19 | — | — | US | disclosed |
| US-8846686-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014025942-A1 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | disclosed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
| EP-1057801-A2 | Process for benzylic bromination | ALBEMARLE CORPORATION (US) | 2000-12-06 | — | — | EP | disclosed |
| US-5698580-A | TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0770609-A1 | ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT | Rational Drug Design Laboratories (JP) | 1997-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | CA1 2903/4885CA2 1549/4885CA12 3122/4885 |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | CA1 4398/4885CA2 3023/4885CA12 3347/4885 |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | CA1 2828/4885CA2 1926/4885CA12 4147/4885 |
| US-20150196540-A1 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO | GRIN2C, GRIN2A, GRIN3A | CA1 735/4885CA2 1595/4885CA12 2318/4885 |
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, ATRIP, CHEK1 | CA1 2764/4885CA2 1593/4885CA12 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.